Jean Bastin

Toxicologie, Pharmacologie et Signalisation céllulaire - UMR-S 1124
Université Paris Descartes
45 rue des Saints Pères
75270 Paris Cedex 06

Fax : +33 (0) 1 42 86 38 68

Dr. Jean BASTIN

INSERM researcher, DR- INSERM
Inborn mitochondrial diseases : pharmacological therapy and metabolic signaling

jean.bastin@-Code a retirer pour éviter le SPAM-inserm.fr
+33 1 42 86 22 19, room P470

Our research work aims I) at the identification of molecules, drugs or natural compounds that will correct inborn mitochondrial disorders (defects in fatty acid oxidation, FAO or the respiratory chain, RC) and II) at the identification of new putative therapeutic targets in diverse signaling pathways. Our research is performed mainly on primary cultures of cells obtained from FAO- or RC-deficient patients who have well characterized mutations which allows the pre-clinical evaluation of candidate compounds in a context of personalized medicine.

After receiving a Ph.D. and postdoctoral training in developmental physiology and biochemistry, Dr. J. Bastin started his research career by working on postnatal development of energy metabolism, with a particular interest in the nutritional and hormonal regulation of mitochondrial functions in rat pups. After switching to the field of inborn fatty acid oxidation (FAO) and respiratory chain (RC) deficiencies, he headed a team at the National Institute for Health and Medical Science (INSERM)-University Paris Descartes to explore pharmacological approaches based on previous observations in rats. More generally, his group is engaged in pre-clinical research with a particular interest in drug screening, personalized, genotype-based therapy and possible applications to patients. In the last ten years, the group has characterized the potential of bezafibrate, a widely prescribed hypolipidemic drug, for the correction of various FAO and RC disorders, in panels of patients’ cells. Dr. Bastin’s team also recently established the beneficial effects of resveratrol, a natural polyphenol compound, in these disorders. Altogether, this research emphasizes the potential of pharmacological approaches to boost mitochondrial functions in genetically-deficient cells and, now, it is admitted that this approach might find applications for the treatment of common disorders.

Recent Publications

Articles